Literature DB >> 8737743

Effect of manoalide on human 5-lipoxygenase activity.

F Cabré1, A Carabaza, N Suesa, A M García, E Rotllan, M Gómez, D Tost, D Mauleón, G Carganico.   

Abstract

The marine natural product manoalide (MLD) has been described to inactivate phospholipase A2 (PLA2) from several sources as well as to inhibit synthesis of eicosanoids in human polymorphonuclear leukocytes (HPMNL). MLD also reduces chemically-induced inflammation in vivo. In this investigation we have examined the effect of MLD on A23187-induced generation of leukotriene B4 (LTB4) and thromboxane B2 (TXB2) in HPMNL as well as 5-lipoxygenase (5-LO) activity from HPMNL sonicated preparations. In the intact cell system, MLD inhibited with similar potency biosynthesis of LTB4 and TXB2 (IC50 1.7 and 1.4 microM, respectively). In order to discern if inhibition of 5-LO is involved in the effect of MLD, we examined the action of this compound on 5-LO activity from 10,000 x g and 100,000 x g supernatants of sonicated HPMNL homogenates. The enzymatic activity was not affected at concentrations of MLD up to 50 microM. These data indicate that MLD is not a direct inhibitor of 5-LO activity from HPMNL and support the hypothesis that its anti-inflammatory action could be related with a reduction of eicosanoid biosynthesis via inhibition of PLA2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737743     DOI: 10.1007/bf02259606

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  25 in total

1.  Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.

Authors:  L A Marshall; J Bauer; M L Sung; J Y Chang
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

2.  New isoflavonoids as inhibitors of porcine 5-lipoxygenase.

Authors:  C Voss; S Sepulveda-Boza; F W Zilliken
Journal:  Biochem Pharmacol       Date:  1992-07-07       Impact factor: 5.858

3.  L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

Authors:  J Gillard; A W Ford-Hutchinson; C Chan; S Charleson; D Denis; A Foster; R Fortin; S Leger; C S McFarlane; H Morton
Journal:  Can J Physiol Pharmacol       Date:  1989-05       Impact factor: 2.273

4.  Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.

Authors:  R M McMillan; K E Spruce; G C Crawley; E R Walker; S J Foster
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

5.  Inactivation of human synovial fluid phospholipase A2 by the marine natural product, manoalide.

Authors:  P B Jacobson; L A Marshall; A Sung; R S Jacobs
Journal:  Biochem Pharmacol       Date:  1990-05-15       Impact factor: 5.858

6.  Regulation of CD11b/CD18 expression in human neutrophils by phospholipase A2.

Authors:  P B Jacobson; D J Schrier
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

7.  Phosphonate-phospholipid analogues inhibit human phospholipase A2.

Authors:  L A Marshall; B Bolognese; W Yuan; M Gelb
Journal:  Agents Actions       Date:  1991-09

8.  Molecular pharmacology of manoalide. Inactivation of bee venom phospholipase A2.

Authors:  K B Glaser; R S Jacobs
Journal:  Biochem Pharmacol       Date:  1986-02-01       Impact factor: 5.858

9.  Regulation of eicosanoid biosynthesis in vitro and in vivo by the marine natural product manoalide: a potent inactivator of venom phospholipases.

Authors:  A M Mayer; K B Glaser; R S Jacobs
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

10.  Cobra venom phospholipase A2 inhibition by manoalide. A novel type of phospholipase inhibitor.

Authors:  D Lombardo; E A Dennis
Journal:  J Biol Chem       Date:  1985-06-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.